BioPharma Resources

Drug Trial Radar · NCT04821089

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines

A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 727 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

727

Planned (sponsor's estimate)

Start

Apr 6, 2021

Primary completion

Aug 19, 2027

Study completion Aug 19, 2027

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy profile of increasing doses of Corabotase (also known as IPN10200) in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines. This study will be conducted in three stages. The full study (including all stages) will have a maximum 727 participants. Stage 1 (phase Ib \& II) * Step 1 (Phase Ib): a dose-escalation first-in-human step in participants with moderate to severe Glabellar Lines (GL) * Step 2 (Phase II): dose ranging step in participants with moderate to severe GL as compared with Dysport * Step 3 (Phase II): dose finding step in participants with moderate to severe GL as compared with Dysport, followed by an open label (OL) phase for the highest dose cohort to assess the long-term safety and efficacy of Corabotase. In the OL phase, participants may receive repeat administrations of Corabotase for up to three additional cycles (up to four treatment cycles in total during the study). Stage 2 (phase II) - An evaluation of efficacy and safety of Corabotase in one of the following regions: GL + forehead lines (FHL), forehead lines (FHL) or lateral canthal lines (LCL) Stage 3 (phase II) \- A safety and efficacy evaluation of Corabotase in all three regions (GL, FHL and LCL)

Conditions

  • Moderate to Severe Upper Facial Lines

Interventions

  • CorabotaseBiological

    Stage 1: Several different doses will be administrated in a dose-escalation manner. One single injection will be injected locally into several sites across the glabellar region. Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions. Stage 3: One single injection will be injected locally into several sites across the upper facial area.

  • IPN10200 PlaceboBiological

    Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region. Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions. Stage 3: One single injection will be injected locally into several sites across the upper facial area.

  • DysportBiological

    Single administration of study intervention in stage 1 / step 2 and 3 only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse events (TEAEs) at each doseTime frame: From the baseline to the end of the study (9 months)
  2. Incidence of serious adverse events (SAEs) at each doseTime frame: From the baseline to the end of the study (9 months)
  3. Incidence of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)Time frame: From the baseline to the end of the study (9 months)
  4. Response to treatment at Stage 2 for the FHL groupTime frame: At Week 4
  5. Response to treatment at Stage 2 for the glabellar lines (GL)+ FHL groupTime frame: At Week 4
  6. Response to treatment at Stage 2 for the LCL groupTime frame: At Week 4
  7. Percentage of Participants With Clinically Significant Changes from baseline in Vital SignsTime frame: From the baseline to the end of the study (6 years, 5 months)
  8. Percentage of participants with clinically significant Change from baseline in 12-lead Electrocardiogram (ECG) readingsTime frame: From the baseline to the end of the study (6 years, 5 months)
  9. Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination.Time frame: From the baseline to the end of the study (6 years, 5 months)

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • MEDITI - Clinique Del Mar

    Antibes, France

  • Aimed S.A.S

    Lyon, France

  • Clinique de Chirurgie Esthétique Iéna

    Paris, France

  • CRS Clinical Research Services Berlin GMBH

    Berlin, Germany

  • Interdisciplinary Study Association

    Berlin, Germany

  • ROSENPARK RESEARCH GmbH

    Darmstadt, Germany

  • Privatpraxis Dr. Hilton & Partner

    Düsseldorf, Germany

  • Fachbereich Chemie Institut für Biologie und Molekularbiologie Studiengang Kosmetikwissenschaft

    Hamburg, Germany

  • Dermatologische Gemeinschaftspraxis Blankenfelde-Mahlow

    Mahlow, Germany

  • Interdisciplinary Study Association

    Kassel, State of Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.